Author

M. Gutierrez-Gonzalez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Approach:statistical model· 1 Assay:structural biology· 1

Frequent Co-Authors

A. S. Fahad· 2 shared B. J. DeKosky· 2 shared B. Madan· 2 shared A. D. Laflin· 1 shared A. Nazzari· 1 shared A. R. Henry· 1 shared A. S. De Groot· 1 shared A. S. Olia· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. S. Fahad

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes

M. Gutierrez-Gonzalez, A. S. Fahad, M. Ardito, P. Nanaware, L. Lu, E. Normandin, B. Madan, J. Tivin, E. Coates, A. R. Henry, F. Laboune, B. S. Graham, D. C. Douek, J. E. Ledgerwood, J. R. Mascola, , B. J. DeKosky

The paper shows that MHC-II epitope removal from BCRs correlates with antibody development, T cell help, and long-term serum antibody secretion.

bioRxiv · Jan 15, 2021 · PreprintImmunology

Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses

B. B. Banach, G. Cerutti, A. S. Fahad, C.-H. Shen, M. Oliveira de Souza, P. S. Katsamba, Y. Tsybovsky, P. Wang, M. S. Nair, Y. Huang, I. M. Francino Urdaniz, P. J. Steiner, M. Gutierrez-Gonzalez, L. Liu, S. N. Lopez Acevedo, , B. J. DeKosky

This study identifies a public antibody class, IGHV3-53/3-66, with potent SARS-CoV-2 neutralization capabilities through paired heavy and light chain interactions.

bioRxiv · Dec 31, 2020Immunology